MREO:NASDAQMereo BioPharma Group plc Analysis
Data as of 2026-08-26 - not real-time
$0.29
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $0.2885, Mereo BioPharma Group plc shows a bearish moving-average alignment, with shorter averages beneath longer ones. The last 30 days have lost 10.2%. Relative strength is 41.5 — neutral — and the MACD signal is bearish. Recent trading has carved out support near $0.2660 and resistance around $0.3700.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 596.9% above where the shares trade now.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 70.0%, a beta of 1.49 and a maximum drawdown of 89.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
This one splits by horizon — sell in the near term, hold further out, at 1/10 long-term conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 596.9% above where the shares trade now.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 70.0%, a beta of 1.49 and a maximum drawdown of 89.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
This one splits by horizon — sell in the near term, hold further out, at 1/10 long-term conviction.
Top Market Events
The rare-disease biotech cut its quarterly net loss while a new Sentynl agreement could provide $40 million in upfront...Nasdaq15dMereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1...14dMereo BioPharma Extends Cash Runway Into Late 2027 as Alvelestat Phase 3 Partnership AdvancesThe rare-disease...
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 0.63
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 0.63
- Analyst targets imply +596.9% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Analyst targets imply +596.9% versus the current price
- Negative return on equity of -67.8%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
P/E Ratio-12.2
ROE-67.85%
ROA-42.46%
Debt/Equity3.60
P/B Ratio1.6
Op. Cash Flow$-25346000
Free Cash Flow$-13656500
Industry P/E31.1
Technical Analysis
TrendBearish
RSI41.5
Support$0.27
Resistance$0.37
MA 20$0.31
MA 50$0.31
MA 200$0.63
MACDBearish
VolumeDecreasing
Fear & Greed Index93.34
Valuation
Target Price$2.01
Upside/Downside596.92%
GradeFair
TypeBlend
Risk Assessment
Beta1.49
Volatility69.95%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.